Drug intelligence / Profile preview

VGV-S

Development stage: Preclinical
Lead developer: VG Life Sciences
Modality: Recombinant Proteins and Enzymes, Peptides
Administration: Injection

Overview

VGV-S is a drug candidate developed by Viral Genetics, leveraging its proprietary Targeted Peptide Technology (TPT), Thymus Nuclear Protein (TNP), and Metabolic Disruption Technology (MDT) platforms. These technologies form the basis of Viral Genetics' pipeline, which is focused on developing therapies for autoimmune diseases, infectious diseases, and cancer.

Beyond the preview

Go deeper on VGV-S.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VGV-S.